Treatment prospects for post-COVID-19 cardiac patients

Pruc, Michał; Merza, Yaroslaw; Filipiak‬, Krzysztof J.; Navolokin, Ihor; Szarpak, Łukasz

doi:10.5603/cj.a2022.0022

Cited by 2 publications

(3 citation statements)

References 10 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At the same time, the pandemic itself was associated with less frequent detection of arterial hypertension, less frequent laboratory tests in the field of lipid disorders, generating the so-called health debt in many countries [14]. Therefore, there is a need to make up for this debt and to intensify the treatment of hypertension and lipid disorders in all our countries [15]. Irrespective of which country was analyzed, in each of the countries, the percentage of patients with hypertension ranges from 26% to 40% and patients with hypercholesterolemia -from 15% to 53%.…”

Section: Times To Actmentioning

confidence: 99%

Section: Times To Actmentioning

confidence: 99%

See 1 more Smart Citation

TIMES TO ACT. Italian-Spanish-Polish-Uzbek Expert Forum Position Paper 2022. Dyslipidemia and arterial hypertension: The two most important and modifiable risk factors in clinical practice

Filipiak‬¹,

Babkowski

Cameli

et al. 2022

Cardiol J.

Self Cite

View full text Add to dashboard Cite

Hypertension and lipid disorders are two of the main cardiovascular risk factors. Both risk factors -if detected early enough -can be controlled and treated with modern, effective drugs, devoid of significant side effects, available in four countries as different as Italy, Spain, Poland, and Uzbekistan. The aim herein, was to develop this TIMES TO ACT consensus to raise the awareness of the available options of the modern and intensified dyslipidemia and arterial hypertension treatments. The subsequent paragraphs involves consensus and discussion of the deleterious effects of COVID-19 in the cardiovascular field, the high prevalence of hypertension and lipid disorders in our countries and the most important reasons for poor control of these two factors. Subsequently proposed, are currently the most efficient and safe therapeutic options in treating dyslipidemia and arterial hypertension, focusing on the benefits of single-pill combination (SPCs) in both conditions. An accelerated algorithm is proposed to start the treatment with a PCSK9 inhibitor, if the target low-density-lipoprotein values have not been reached. As most patients with hypertension and lipid disorders present with multiple comorbidities, discussed are the possibilities of using new SPCs, combining modern drugs from different therapeutic groups, which mode of action does not confirm the "class effect". We believe our consensus strongly advocates the need to search for patients with cardiovascular risk factors and intensify their lipid-lowering and antihypertensive treatment based on SPCs will improve the control of these two basic cardiovascular risk factors in Italy, Spain, Poland and Uzbekistan.

show abstract

Section: Times To Actmentioning

confidence: 99%

Section: Times To Actmentioning

confidence: 99%

TIMES TO ACT. Italian-Spanish-Polish-Uzbek Expert Forum Position Paper 2022. Dyslipidemia and arterial hypertension: The two most important and modifiable risk factors in clinical practice

Filipiak‬¹,

Babkowski

Cameli

et al. 2022

Cardiol J.

Self Cite

View full text Add to dashboard Cite

show abstract

“…The underlying mechanisms of cardiac injury in COVID-19 are not fully understood but may involve direct viral invasion, systemic inflammation, endothelial dysfunction, and microthrombi formation. Cardiac markers can help shed light on these mechanisms and provide valuable information for risk stratification and targeted therapies [ 7 ].…”

mentioning

confidence: 99%